Global Histone Deacetylase Inhibitors Market

Histone deacetylase (HDAC) is enzymes, which inhibits histone deacetylase by removing scetyl group from n-acetyl lysine amino acid. Histone deacetylase inhibitors are emerging as potential application in diagnosis, treatment and prognosis of cancer. It is also considered as a treatment option for hematological malignancies and plays important role in epigenetic or non-epigenetic regulation. The histone deacetylase inhibitors accumulates acetylated nuclear histone in tumors and normal tissues. Thus, the inhabitation results in acetylation transcription factors such as GATA-1, p53 and estrogen receptor-alpha. These enzymes are found in fungi, bacteria, animals and plants. There are around 18 human histone deacetylase known, which are classified into four classes based on their structures. Class I HDAC1, HDAC2, HDAC3, and HDAC8. Class II includes HDAC4, HDAC5, HDAC7, and HDAC9. Class III includes HDAC6 and HDAC10, whereas Class IV includes HDAC11.

The demand for histone deacetylase inhibitors is rapidly increasing owing to growing need for innovative therapies for cancer treatment. Histone deacetylase inhibitors plays vital role in regulation of gene expression via the effects on the chromatin structure. Over the past few years, numerous histone deacetylase inhibitors molecules have undergone clinical trials for different types of cancer. These inhibitors are categorized based on their chemical structure. Among these categories hydroxamic acid-based compounds are the most widely explored class of histone deacetylase inhibitor.

Histone deacetylase inhibitors market has been segmented on the basis of class, application, end user and geography.

Based on application, the market is categorized into oncology, neurology, and other disease. Oncology is expected to be the leading segment owing to the large patient base and increasing need for novel therapies for the treatment of cancer patients. Currently, FDA have approved four products namely, Romidepsin (Istodax), orinostat (Zolinza), Vidaza and Dacogen. However, pharmaceutical companies are now heavily investing into research and development activities and preclinical activities of histone deacetylase inhibitors for different applications.

Based on the end user segment, the histone deacetylase inhibitors market is categories into hospitals, oncology clinics and other end users. Oncology clinics end user segment is expected to be the highest revenue generating segment owing to the increasing adoption of novel therapies for cancer treatment and increasing incidence of cancer across the globe. Similarly, growing expenditure on R&D activities by pharmaceutical companies and increasing government funding for such activities is expected to drive the growth for the histone deacetylase inhibitors market during the forecast period.

Global histone deacetylase inhibitors market is experiencing significant growth owing to the increase incidence of different types of cancer and growing need for effective cancer diagnosis and therapeutics. Moreover, increasing R&D activities for the cancer treatment and other neurological disorders is one of the prime factor responsible for the market growth. However, unfavorable reimbursement policies and uncertainty issues of HDAC inhibitors might hamper the market growth to some extent.

Geographically Histone deacetylase inhibitors market is classified into regions viz. North America, Latin America, Europe, Asia-Pacific, Middle East and Africa. North America and Europe will remain key markets for Histone deacetylase inhibitors market due to presence of sophisticated healthcare infrastructure, high R&D spending capacity and early adoption of innovative therapeutics. Asia Pacific is anticipated to register positive growth owing to rising government’s initiatives in healthcare sector, improved healthcare infrastructure and increasing cancer patients population in the region.

A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/14407

Some of the key players in the histone deacetylase inhibitors market are Celgene Corporation, Celleron Therapeutics Ltd, Eisai Co., Ltd., Novartis International AG, Acetylon Pharmaceuticals, Inc., AstraZeneca plc., Merck & Co., Inc. Pfizer Inc. to name a few.

Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/14407

About Us
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated re-search, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Con-sumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s en-gagement models are highly flexible without compromising on its deep-seated research values.

Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Web:http://www.persistencemarketresearch.com

This release was published on openPR.